High-Throughput LNP Screening Using DNA and mRNA Barcoding Technologies

Introduction: The Delivery Problem in Nucleic Acid Therapeutics

Nucleic acid therapeutics—such as mRNA vaccines, siRNA drugs, and CRISPR-based gene editors—have transformed modern medicine. However, the clinical success of these modalities depends not only on the therapeutic payload itself, but critically on how efficiently and selectively it can be delivered in vivo.

Lipid nanoparticles (LNPs) have emerged as the gold-standard platform for systemic nucleic acid delivery. By protecting fragile nucleic acids from degradation and facilitating cellular uptake, LNPs have enabled landmark products such as Onpattro®, Comirnaty®, and Spikevax®.

Yet, LNP design remains a complex, multidimensional optimization problem. Minor changes in ionizable lipid chemistry, molar ratios, PEG density, or lipid tail structure can dramatically alter biodistribution, transfection efficiency, and immunogenicity. Historically, formulation screening relied on one-formulation-per-animal experiments using fluorescent reporters or luciferase assays—an approach that is slow, costly, and poorly scalable.

Recent advances in high-throughput LNP screening enabled by DNA and mRNA barcoding technologies have fundamentally changed this paradigm. By allowing dozens to hundreds of LNP formulations to be evaluated simultaneously in a single animal, barcoding-based approaches are rapidly accelerating delivery optimization and redefining how nucleic acid therapeutics are developed.

Part 1: DNA Barcoding — Revolutionizing High-Throughput LNP Screening

The Concept of DNA Barcoding

DNA barcoding employs short, synthetic DNA sequences—each serving as a unique molecular identifier—encapsulated within distinct LNP formulations. After pooling and systemic administration, tissues are harvested and barcode abundance is quantified using qPCR, ddPCR, or next-generation sequencing (NGS).

This approach enables direct, quantitative comparison of biodistribution across many LNP formulations under identical in vivo conditions, eliminating a major source of experimental variability.

Key Advantages of DNA Barcoding

• Parallel screening of up to hundreds of LNP formulations in a single animal

• Elimination of inter-animal variability

• Quantitative, organ-resolved biodistribution profiling

• Significant reduction in cost, animal use, and development timelines

Barcode Design Principles

Effective DNA barcoding systems typically follow several core design rules:

• Synthetic DNA fragments ~100–120 bp in length

• Universal primer binding sites flanking the barcode region

• Non-homologous, non-coding sequences

• Minimal secondary structure to ensure uniform amplification efficiency

LNP Library Diversity in Barcoded Screens

Barcode libraries can encode extensive formulation diversity, including variations in:

• Ionizable lipids (e.g., MC3, SM-102, or novel proprietary chemistries)

• Helper lipids such as DSPC or DOPE

• Cholesterol content and ratios

• PEG-lipid identity, chain length, and density

Each formulation is uniquely barcoded, pooled at defined ratios, and administered simultaneously.

In Vivo High-Throughput Screening Workflow

1. Formulate and QC individual barcoded LNPs

2. Pool formulations into a single injectable library

3. Administer in vivo (e.g., intravenous or targeted routes)

4. Harvest organs (liver, spleen, lung, lymph nodes, etc.)

5. Extract nucleic acids from tissues

6. Quantify barcode abundance via qPCR, ddPCR, or NGS

Case Study: Lung-Tropic LNP Discovery

In a 2024 Nature Communications study, researchers screened 96 barcoded LNP formulations and identified CAD9 as a highly lung-tropic lipid, achieving over 90% localized protein expression in lung tissue. This work demonstrated how barcoding-based screening can rapidly uncover organ-selective delivery chemistries that are difficult to identify using traditional methods.

Benchmarking Commercial LNP Formulations

In 2025, barcoded versions of clinically approved LNPs—including Onpattro®, Comirnaty®, and Spikevax®—were evaluated side-by-side. The study confirmed their distinct and reproducible biodistribution profiles, validating DNA barcoding as a high-resolution, biologically meaningful screening platform.

Strengths and Limitations of DNA Barcoding

Strengths

• Extremely high throughput

• Robust and reproducible biodistribution mapping

• Scalable to large formulation libraries

Limitations

• Reports distribution rather than functional expression

• Cannot directly measure translation efficiency or protein output

• Requires careful normalization and sequencing depth control

Part 2: Peptide-Encoding mRNA Barcodes — Linking Delivery to Function

From Biodistribution to Functional Readout

While DNA barcodes reveal where LNPs go, they do not report what happens inside the cell. To bridge this gap, researchers developed peptide-encoding mRNA barcodes, which directly couple delivery efficiency with translational output.

These barcodes consist of mRNAs encoding short, unique peptide tags. Upon successful delivery and translation, peptide abundance can be quantified using mass spectrometry or antibody-based assays.

Design of Peptide-Encoding mRNA Barcodes

• Each mRNA encodes a unique 8–10 amino acid peptide tag

• Optimized Kozak sequences and start/stop codons

• Avoidance of known immunogenic motifs and destabilizing elements

Functional Screening Workflow

1. Encapsulate peptide-encoding mRNA barcodes into LNPs

2. Pool and administer formulations in vivo

3. Allow intracellular translation in target tissues

4. Extract proteins from tissues

5. Quantify peptide abundance via LC–MS or multiplex ELISA

Case Study: Multiplexed Functional Screening

Recent studies demonstrated that peptide barcoding enables simultaneous, quantitative measurement of both delivery and protein expression across multiple LNP formulations. This approach revealed subtle structure–function relationships that are invisible to DNA-only barcoding and provided richer data for formulation optimization.

DNA Barcoding vs. Peptide-Encoding mRNA Barcoding

Feature	DNA Barcoding	Peptide-Encoding mRNA
Throughput	Very high	High
Biodistribution mapping	✅	Indirect
Functional expression readout	❌	✅
Assay complexity	Lower	Higher
Data richness	Moderate	High

Rather than competing approaches, these technologies are highly complementary.

Toward Intelligent and Scalable LNP Design

By integrating barcoding-based high-throughput LNP screening with combinatorial lipid chemistry, automation, and machine learning, the field is moving toward predictive delivery design pipelines.

Increasingly, barcode-derived datasets are being used to:

• Train ML models that predict organ targeting

• Guide rational ionizable lipid design

• Optimize formulations earlier in development

• Reduce costly late-stage reformulation cycles

Peptide-encoding barcodes further close the loop between chemical structure, biodistribution, and functional efficacy—transforming LNP development from empirical trial-and-error into a data-driven engineering discipline.

Conclusion: The Future of LNP Development Is Multiplexed

Barcoding technologies are redefining how lipid nanoparticles are designed and evaluated.

• DNA barcodes reveal where LNPs go

• Peptide-encoding mRNA barcodes reveal what they do

Used together, they enable scalable, high-resolution optimization of delivery platforms for vaccines, gene therapies, and next-generation nucleic acid medicines.

🔬 Technical LNP Consulting Services

Learn More

Designing effective lipid nanoparticle (LNP) systems requires more than screening data—it demands deep integration across formulation science, in vivo biology, analytics, and scale-up considerations.

If your team is working on:

• High-throughput LNP screening or barcoding-based evaluation platforms

• Ionizable lipid selection and formulation optimization

• Translating in vivo biodistribution data into actionable design rules

• Bridging early discovery with CMC, scale-up, or IND-enabling studies

I provide technical LNP consulting services to support biotech startups, platform teams, and R&D groups navigating these challenges.

My background spans hands-on LNP formulation, barcoding-based in vivo screening, nucleic acid delivery, and cross-functional collaboration with biology, analytics, and CMC teams—with experience in both academic and early-stage biotech environments.

If you’re interested in discussing how high-throughput delivery evaluation or rational LNP design can accelerate your program, feel free to connect:

Contact Me

References

• Xue et al., Nature Communications, 2024

• Liu et al., Colloids and Surfaces B: Biointerfaces, 2025

• Paunovska et al., Nano Letters, 2018

• Dahlman et al., Nature Nanotechnology, 2020

• Mitchell et al., Nature Reviews Drug Discovery, 2021